Cell Culture. Murine macrophages were washed from the peritoneal cavities offemale CDl mice (Charles River Breeding Laboratories, Wilmington, MA) . Where indicated, mice were injected intraperitoneally with 2 ml of thioglycollate broth (Brewer, 4%) 4 d earlier as described (18) . Adherent monolayers were obtained by plating 8 x 105 cells per well in 24-well plastic trays or 2 x 105 cells per well in 96-well plastic trays in RPMI 1640 (KC Biological, Inc., Lenexa, KS) containing 10% heat-inactivated FCS (HyClone Laboratories, Logan, UT) . Monolayers were maintained at 37°C in 5% C02/95 17o air for 1-4 d before the experiments . Human macrophages were allowed to mature from peripheral blood monocytes in Teflon beakers as described (19) . Second-passage human umbilical vein endothelial cells were the gift ofDr. EricJaffe (Cornell University Medical College, New York, NY) and were prepared as described (20) . Human polymorphonuclear leukocytes (PMN) were isolated from heparinized venous blood on Neutrophil Isolation Medium (Los Alamos Diagnostics, Los Alamos, NM) as described (21) .
Iodination ofrTNF-a and rIFN-y. Human rTNFa and murine rIFN-y were iodinated according to the method o£ Aggarwal et al. (22) , and stored at VC for no longer than 6 wk. In brief, 100 p.l of 0.1 M phosphate buffer (pH 7 .4) was added to a glass tube coated with 5 lAg of Iodogen (Pierce Chemical Co., Rockford, IL) and incubated with 1 mCi of Na' 25I for 10 min at 4oC . The mixture was then transferred to a tube containing 10 Rg of rTNFa or rIFN-y for 10 min at 4°C . The reaction was stopped by addition of one drop of 1 M KI. Iodinated material was separated from free iodide by filtration through a PD-10 column (Pharmacia Fine Chemicals, Piscataway, NJ) that had been equilibrated with 0.1 M phosphate (for rTNF-a) or 20 mM Tris buffer (for rIFN-y), both containing 0.1% gelatin, pH 7.4. '25 1-rTNFa had a specific activity of -300 Ci/mmol monomer, and migrated as a single band with an apparent molecular mass of -16 kD on an 1117o polyacrylamide gel under nonreducing conditions. '21 I-rIFN-y had a specific activity of -100 Ci/mmol monomer. Both cytokines retained their ability to activate resident mouse peritoneal macrophages for enhanced H202 release (18) .
Receptor Binding Assay. Cell monolayers in 24-well trays were overlaid with 0.3 ml per well ofbinding buffer (HBSS containing 10% FCS) and incubated with indicated concentrations of 1251-rTNFot in the presence or absence of a 100-fold excess of unlabeled rTNFa . After 3-4 h at 4oC, binding buffer was removed and the monolayers rinsed four times with ice cold 0.9% NaCl. Cells were solubilized in 0.3 ml of 0.3 N NaOH and radioactivity determined in a gamma counter (Packard Instrument Co., Downers Grove, IL). Binding to human PMN in suspension was carried out as described (10) . Nonspecific binding was <15% of the total and was subtracted to calculate specific binding . When the effects of drugs were examined, the cells were incubated with the drugs for 1 h at 37'C before the binding assay.
To assay IFN-y receptor (IFN-yR), the above method was modified to reduce sticking of radiolabeled rIFN-y to plastic : (a) Binding was carried out at room temperature instead of 4oC. (b) Binding buffer was changed to RPMI 1640 containing 50 MM Hepes, 10 mM NaN3, and 1% (wt/vol) BSA . (c) Cell-bound "'I-rIFN-y was eluted with 50 mM glycine in saline, pH 3, at 4oC for 5 min (in contrast, '25 1-rIFN-y bound to plastic can be eluted with NaOH). Nonspecific binding was <l0olo of the total, and was subtracted to calculate specific binding .
Hydrogen Peroxide Release. H202 secretion was measured fluorometrically by the horseradish peroxidase-catalyzed oxidation offluorescent scopoletin to a nonfluorescent product, as described in detail (23) . The protein content of cells adherent at the start of the assay in each well was measured by the method of Lowry et al. (24) with BSA as a standard. Specific release was calculated after subtracting H202 and protein values from the cell-free wells.
Measurement of LPS . LPS contamination of reagents was monitored by a chromogenic limulus amebocyte lysate test (Whittaker Bioproducts, Inc., Walkersville, MD) with a sensitivity of -10 pg/ml.
Results
Decreased 125 1-rTNFa Binding to Macrophages after Preincubation with MT Depolymerizing Agents. It was established previously that murine macrophages bind "'I-labeled human rTNFa specifically and reversibly (10) . Preexposure of macrophages to 3 IM nocodazole for 1 h at 37°C inhibited the subsequent binding of 125 1-rTNFa at 4°C (Fig . 1) . Scatchard analysis of the data indicated that nocodazole affected the numbers of receptor sites rather than their affinity (Fig. 1, inset) . TNFceR of human macrophages were reduced in a similar fashion in response to colchicine in two experiments (not shown) . Mouse macrophages were used to characterize this effect further.
Pretreatment with three other MT depolymerizing agents, vincristine, vinblastine, and podophyllotoxin, also diminished subsequent 125 1-rTNF a binding in a concentration-dependent manner (Fig . 2) . In contrast, (3-and y-lumicolchicine, which do not depolymerize MT, did not suppress binding of 125 1-rTNF a. The microfilamentdisrupting agents cytochalasin B, dihydrocytochalasin B, and cytochalasin E had little or no effect ( Table I) . As a control, the effect of colchicine on IFN-,YR, another cytokine receptor on the macrophage surface, was tested under the same conditions . Binding of rIFN-y was not affected by colchicine or nocodazole (Table I ) . This suggested that the effects of colchicine and nocodazole on TNFaR did not result from nonspecific toxicity.
Downregulation of TNFaR by MT depolymerizing agents depended on temperature. In contrast to results at 37°C, preexposure of macrophages to 10,M colchicine or 10 tLM nocodazole at 4°C caused no detectable change in 125 1-rTNFa binding. Nor did colchicine or nocodazole compete with TNFa binding sites at 4°C (not shown) .
Recovery of TNFciR after exposure to MTdepolymerizing agents correlated with the reversibility of their binding to tubulin. After a 1-h exposure to 10 ,,M colchicine or 3 1.M nocodazole, macrophages were incubated in drug-free medium for various periods before the 125 1-rTNFa binding assay (Fig. 3) . Colchicine binds irreversibly to tubulin (25) . The ability of macrophages to bind rTNFci continued to decrease for at least 4 h after a 1-h exposure to colchicine, by which time binding capacity had decreased 75%. 18 h after the 1-h exposure to colchicine, the capacity of the cells to bind rTNFu was still suppressed by 46% . Nocodazole binds reversibly to tubulin (26) ; its effect on binding of rTNFa was 50% reversed by 1 h after its removal.
Effect ofAntibody Against Murine TNF-a . Since macrophages secrete TNFa, it was possible that MTdepolymerizing agents downregulated TNFaR by triggering endogenous TNFci release, leading to internalization ofligand-receptor complexes. To test this, we made use of a neutralizing antiserum (15E) against murine TNFa. When present during the pretreatment of the cells with colchicine or nocodazole, 15E (sufficient to neutralize 1000 U/ml TNFa) did not prevent the subsequent decrease in ability of the cells to bind exogenous rTNFci (Table II) . As a positive con- trol, in studies to be reported elsewhere (Ding, A. H., F Porteu, E. Sanchez, and C. E Nathan, manuscript submitted for publication), antibody 15E did block downregulation of TNFaR in response to a drug that elicits TNFa release (not shown) .
Role of the Cyclooxygenase Pathway. Colchicine has been reported to induce the synthesis of cyclooxygenase products, leading to an increase in the intracellular level ofCAMP (27, 28) . To test whether this pathway was involved in the colchicine-induced downregulation of TNFciR, macrophages were exposed to PGEI or dibutyrylcAMP, a lipid soluble analog of cAMP, for 1 h at 37°C, and then the binding of 121 1-rTNFa was assessed . Neither of these agents decreased 121 1-rTNFa binding (Table III) . In fact, high concentrations of PGEI or dibutyryl-CAMP had the opposite effect . Moreover, the cyclooxygenase inhibitors indomethacin (10-7 to 10-1 M), ibuprofen (10' to 10-5 M), and acetylsalicylic acid (10-5 to 10 -3 M) did not prevent colchicine-induced downregulation of TNFaR (data not shown) .
Role of LPS . Since TNFaR of macrophages and endothelial cells can be downregulated by traces of LPS (10), a common contaminant of commercial reagents, the LPS content of all the MTdepolymerizing agents used in this study was deter- mined. At the concentrations of drugs used, the LPS content was <10 pg/ml, i.e., below the minimum effective concentration of LPS (10) . Moreover, as assessed by immunofluorescence microscopy, the MT network remained intact in LPS-treated macrophages, even though MT disappeared in macrophages treated with MT depolymerizing agents (not shown) . Thus the effect of MTdepolymerizing agents on TNFaR was not due to LPS, and the effect of LPS on TNFceR was not due to depolymerization of MT Effect ofCycloheximide. With a human myosarcoma cell line, inhibition of protein synthesis with cycloheximide resulted in decreased surface expression of TNFaR with a half-life of 2 h (29). This suggested that TNFciR on the myosarcoma cells turned over in the absence of ligand, perhaps by internalization, and that de novo protein synthesis was necessary for replacement of TNFciR on the cell surface. If a similar situation existed in macrophages, then MTdepolymerizing agents might reduce binding of rTNF a by interfering with the ability of the cell to replace TNF aR as TNFciR were lost from the cell surface. According to this hypothesis, cycloheximide should inhibit binding of rTNFa to a similar extent and with a similar time course as colchicine . As shown in Fig. 4 , this was the case. Exposure of macrophages to 10 hg/ml of cycloheximide at 37°C resulted in 50% reduction of TNFaR in 60 min in the absence of added ligand . The effect of colchicine on IFN--yR, a receptor known to be insensitive to cycloheximide (30) , was tested under the same conditions. Binding of rIFN-y was not affected by colchicine (Fig. 4) . This suggested that the effects of colchicine and cycloheximide on TNFaR did not result from nonspecific toxicity, and that in the absence of exogenous ligand, TNFaR turns over on the macrophage surface more quickly than IFN--yR.
Inhibition of TNF-a-mediated Macrophage Activation by Colchicine. We next asked if downregulation ofTNFciR by colchicine or cycloheximide would affect TNFa-mediated macrophage activation . Resident macrophages were pulsed for 1 h at 37°C with medium alone, colchicine, or cycloheximide. As an additional control, some macrophages were pulsed with (3-lumicolchicine. After removal ofthese reagents, cells were incubated with increasing amounts of rTNFa for 48 h at 37°C, washed, and ex- Elect of Colchicine on TNF-ciR ofHuman Endothelial Cells and PMN. The interaction of PMN with endothelium plays a central role in the development of inflammation, and can be regulated by TNF a (32). We therefore examined the effect of MT depolymerizing agents on TNF-ciR in human endothelial cells and PMN . As shown in Figs. 6 and 7, 1-h treatment with colchicine or nocodazole resulted in a 38-47% downregulation ofTNFotR in endothelial cells, while (3-lumicolchicine had no effect . The concentration-response curves and kinetics of the effect of these agents on endothelial cells matched those for mouse macrophages, and the Scatchard plots were almost the same (Fig. 6, inset) . Consistent with these findings, endothelial cells also responded to cycloheximide with decreased 125 I-rTNF a binding (Fig. 7) . However, no changes were found in TNFciR when human PMNs in suspension were exposed for 1 h to either 10 gM colchicine or 10 FAg/ml cycloheximide (not shown).
Discussion
Incubation of macrophages or endothelial cells with any one of five MT depolymerizing agents in micromolar concentrations at 37oC resulted in a concentrationdependent downregulation ofsurface TNF otR . As a consequence, macrophages exposed to MTdepolymerizing agents became refractory to TNFci, a rare example Inhibition of TNFa induced H202 release by colchicine and cycloheximide. Resident macrophages were pulsed for 1 h at 37oC with medium (O), 10 AM colchicine (A), 10 /~g/ml of cycloheximide (0), or 10 AM fl-lumicolchicine (A). After removal of drugs, indicated concentrations of rTNFa were added, and incubated with cells for an additional 48 h at 37 oC in a 5% C02/957o air incubator. Then H202 release was determined in the presence of 100 ng/ml of PMA. The results are means t SE for triplicates. [TNFa] (nM) FIGURE 6 . Decreased TNFaR on human endothelial cells after treatment with colchicine . Human endothelial cells were pretreated with (A) or without (O) 10 AM colchicine for 1 h at 37°C. Other conditions were the same as the legend for Fig. 1 .
of inhibition of macrophage activation in vitro by a pharmacological agent in clinical use.
The five effective agents belong to four structurally distinct classes; the only action they are known to share is the ability to depolymerize MT. Inactive isomers of colchicine were ineffective, as were microfilament-destabilizing cytochalasins. The spectra of biologic effects of the drugs, their effective concentrations, and the relative reversibility of their actions provide strong evidence that MT disassembly was responsible for the observed downregulation of TNFaR . Effect of drugs on TNRaR of human endothelial cells. Confluent monolayers of endothelial cells were incubated with medium alone, 10 AM nocodazole, 10 AM colchicine, 10 PM /3-lumicolchicine, or 10 pg/ml cycloheximide for 1 h at 37°C before the binding assay. The results are means t SE for triplicates.
Several mechanisms might have been at work: competition by the MT depolymerizing agents with 121 1-rTNFa for its receptor; triggering of the release of endogenous TNFac, followed by ligand-induced receptor downregulation; activation of protein kinase A via elevation of intracellular cAMP; internalization triggered by LPS contaminating the reagents (10); decrease of TNFctR synthesis; or impairment of transport of newly synthesized TNFuR to the plasma membrane. Our data exclude the first four explanations but are consistent with either of the last two. We could not distinguish whether the effect of colchicine on TNFaR was due to inhibition of TNFciR synthesis, interference with transport of TNFaR to the plasma membrane, or both. The question can only be answered when specific antibodies and cDNA probes for TNFciR become available.
It has been suggested that MT can affect polyribosome stability (33) and mRNA levels (34) . Macrophage and endothelial cell surface TNFaR declined as rapidly after exposure to cycloheximide, an inhibitor of protein synthesis, as they did after exposure to colchicine. Surface receptors for another macrophage-activating cytokine, IFN-yR, were insensitive both to cycloheximide and to colchicine over the same time interval . With another phagocyte, PMN, TNFciR were insensitive both to cycloheximide and to colchicine, consistent with the limited protein synthetic capacity ofPMN. Thus, in different cell types, depolymerization ofcytoplasmic MT appeared to have an impact on the turnover of TNFaR similar to that of interrupting the synthesis of TNFceR.
MT are required for the transport of several kinds of hormone receptors to the plasma membrane. Colchicine prevented the recycling of insulin receptors to the plasma membrane in rat hepatocytes after treatment with high concentrations of insulin (35) . Likewise, colchicine inhibited the recovery ofcardiac myocyte /3-adrenergic receptors after their downregulation by an agonist (36) . MT were required for apical surface expression of a plasma membrane protein ofunknown function in intestinal epithelial cells (37) . Finally, MTdepolymerizing agents interfered with the secretion of a variety of proteins and peptides, including insulin (38) , very low density lipoproteins (39, 40) , fibroblast growth factor (41), lysosomal enzymes (42) , and thyroxine (43) . In contrast to the studies cited above with insulin receptors and adrenergic receptors, downregulation ofTNFciR by colchicine was demonstrable without massive ligand-induced internalization of the receptors. This probably reflected rapid constitutive turnover of TNFaR on macrophages and endothelial cells. In contrast to cycloheximide, none of the MTdepolymerizing agents tested appeared to downregulate TNFuR completely, suggesting that expression of a portion of nascent TNFuR does not depend on the MT network. A similar observation was made for insulin receptors (35) .
Emigration of leukocytes across the endothelium is a critical aspect of inflammation. TNF-ci can play an important role in this process (32) , and can induce macrophages and endothelial cells in such sites to release other inflammatory mediators, such as IL-1, IL-6, neutrophil activating peptides, eicosanoids, and reactive oxygen and nitrogen intermediates (18, (44) (45) (46) (47) (48) . It is possible that the effects of MT depolymerizing agents seen here with macrophages and endothelial cells may also be exerted on some other types of cells on which TNFa has potentially important actions, including synovial cells (49) and lymphocytes (50) . Thus, the downregulation of TNFaR by MT depolymerizing agents may contribute to their antiinflammatory effects.
If pharmacologic compounds that depolymerize MT can modulate TNFaR, perhaps endogenous signals that affect MT function can also affect TNFaR. The polymerization state ofMT is sensitive to the intracellular concentration of calcium (51) . It is also tightly controlled by MT-associated proteins, whose functions, in turn, are regulated by kinases (52) (53) (54) (55) (56) . Our findings raise the possibility that certain hormones or cytokines could modulate the expression of receptors for the same or other hormones or cytokines through the interaction of second messenger systems with the MT network. Summary Exposure ofmurine and human macrophages and human umbilical vein endothelial cells to micromolar concentrations of five microtubule (MT)-depolymerizing agents (colchicine, nocodazole, podophyllotoxin, vincristine, and vinblastine) resulted in a loss of binding sites for iodinated TNFa. The reduction amounted to 40-60% by 1 h and N75% by 2-4 h. In 1 h, specific binding was reduced 50% by 0.1-5 ,UM of these drugs at 37°C, but not at 4°C. Inactive isomers of colchicine were ineffective, as were microfilament-destabilizing cytochalasins. The active agents did not compete with TNFaR for binding. Antiserum against TNFa did not neutralize the effect of colchicine and nocodazole . PGEi and dibutyryl-CAMP could not mimic, and cyclooxygenase inhibitors could not prevent the drug effects. All the binding sites were regenerated within 3 h after removal of nocodazole, which binds tubulin reversibly, whereas little recovery was found even 18 h after the removal of colchicine, which binds tubulin irreversibly. These findings suggested that MT disassembly was responsible for the observed downregulation ofTNFciR. The protein synthesis inhibitor cycloheximide inhibited binding of TNFci to a similar extent and with a similar time course as colchicine in the absence of added ligand . Neither drug affected binding of IFN-y to macrophages, nor binding of TNFU to human polymorphonuclear leukocytes. Thus, an intact MT network appears to be important in maintenance ofthe steady state of TNFciR on those cells in which TNFaR turns over rapidly in the absence of ligand . The andinflammatory actions of MTdepolymerizing agents may result in part from their interference with the ability of such cells to respond to TNF-a.
